Vasoactive intestinal polypeptide/phentolamine for intracavernosal injection in erectile dysfunction

BJU International

Volumn 102, Issue 8, 2008, Pages 933-937

  Dinsmore, W Wallace ^b   Wyllie, Michael G ^a  

^a Plethora Solutions Ltd   (United Kingdom)

^b ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

Aviptadil; Erectile dysfunction; Intracavernosal therapy; Invicorp; Phentolamine; Vasoactive intestinal polypeptide; VIP

Indexed keywords

INVICORP; PAPAVERINE; PHENTOLAMINE MESYLATE; PHENTOLAMINE MESYLATE PLUS VASOACTIVE INTESTINAL POLYPEPTIDE; PLACEBO; PROSTAGLANDIN E1; UNCLASSIFIED DRUG; VASOACTIVE AGENT; VASOACTIVE INTESTINAL POLYPEPTIDE;

ARTERIAL BLOOD; CLINICAL TRIAL; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; ERECTILE DYSFUNCTION; FLUSHING; HEADACHE; HEART PALPITATION; HUMAN; INJECTION SITE BLEEDING; INJECTION SITE CONTUSION; MONOTHERAPY; NONHUMAN; PAIN; PENIS ERECTION; PRIAPISM; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SIDE EFFECT; TACHYCARDIA; URETHRAL BLEEDING;

AGED; DRUG COMBINATIONS; ERECTILE DYSFUNCTION; HUMANS; INJECTIONS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PENILE ERECTION; PHENTOLAMINE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VASOACTIVE INTESTINAL PEPTIDE;

EID: 52649181127     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07764.x     Document Type: Review

References (35)

1. NIH. NIH Consensus Development Panel on Impotence. JAMA 1993 270 : 83 90
2. Porst H. Current perspectives on intracavernosal pharmacotherapy for erectile dysfunction. Int J Impot Res 2000 12 (Suppl. 4 S91 100
3. Pryor JL, Redmon B. New therapies and delivery mechanisms for treatment of erectile dysfunction. Int J Impot Res 2000 12 (Suppl. 4 S158 62
4. Montague DK, Jarow JP, Broderick GA et al. Chapter 1. The management of erectile dysfunction: an AUA update. J Urol 2005 174 : 230 9
5. Jünemann K-P, Alken P. Pharmacotherapy of erectile dysfunction: a review. Int J Impot Res 1989 1 : 71 93
6. Chen JK, Hwang TI, Yang CR. Comparison of effects following the intracorporeal injection of papaverine and prostaglandin E1. Br J Urol 1992 69 : 404 7
7. Giuliano FA, Rampin O, Benoit G, Jardin A. Neural control of penile erection. Urol Clin North Am 1995 22 : 747 66
8. Virag R, Frydman D, Legman M, Virag H. Intracavernous injection of papaverine as a diagnostic and therapeutic method in erectile failure. Angiology 1984 35 : 79 87
9. Larsen JJ, Ottesen B, Fahrenkrug J, Fahrenkrug L. Vasoactive intestinal polypeptide (VIP) in the male genitourinary tract: concentration and motor effect. Invest Urol 1981 19 : 211 3
10. Willis EA, Ottesen B, Wagner G, Sundler F, Fahrenkrug J. Vasoactive intestinal polypeptide (VIP) as a putative neurotransmitter in penile erection. Life Sci 1983 33 : 383 91
11. Willis E, Ottesen B, Wagner G, Sundler F, Fahrenkrug J. Vasoactive intestinal polypeptide (VIP) as a possible neurotransmitter involved in penile erection. Acta Physiol Scand 1981 113 : 545 7
12. Juenemann KP, Lue TF, Luo JA, Jadallah SA, Nunes LL, Tanagho EA. The role of vasoactive intestinal polypeptide as a neurotransmitter in canine penile erection: a combined in vivo and immunohistochemical study. J Urol 1987 138 : 871 7
13. Gu J, Polak JM, Lazarides M et al. Decrease of vasoactive intestinal polypeptide (VIP) in the penises from impotent men. Lancet 1984 2 : 315 8
14. Wagner G, Gerstenberg T. Intracavernosal injection of vasoactive intestinal polypeptide (VIP) does not induce erection in man per se. World J Urol 1987 5 : 171 2
15. Ottesen B, Wagner G, Virag R, Fahrenkrug J. Penile erection: possible role for vasoactive intestinal polypeptide as a neurotransmitter. BMJ 1984 288 : 9 11
16. Roy JB, Petrone RL, Said SI. A clinical trial of intracavernous vasoactive intestinal peptide to induce penile erection. J Urol 1990 143 : 302 4
17. Juenemann KP, Lue TF, Fournier GR Jr, Tanagho EA. Hemodynamics of papaverine- and phentolamine-induced penile erection. J Urol 1986 136 : 158 61
18. Blum MD, Bahnson RR, Porter TN, Carter MF. Effect of local alpha-adrenergic blockade on human penile erection. J Urol 1985 134 : 479 81
19. Kiely EA, Bloom SR, Williams G. Penile response to intracavernosal vasoactive intestinal polypeptide alone and in combination with other vasoactive agents. Br J Urol 1989 64 : 191 4
20. Zentgraf M, Baccouche M, Junemann KP. Diagnosis and therapy of erectile dysfunction using papaverine and phentolamine. Urol Int 1988 43 : 65 75
21. Gerstenberg TC, Metz P, Ottesen B, Fahrenkrug J. Intracavernous self-injection with vasoactive intestinal polypeptide and phentolamine in the management of erectile failure. J Urol 1992 147 : 1277 9
22. Dinsmore WW, Alderdice DK. Vasoactive intestinal polypeptide and phentolamine mesylate administered by autoinjector in the treatment of patients with erectile dysfunction resistant to other intracavernosal agents. Br J Urol 1998 81 : 437 40
23. Dinsmore WW, Gingell C, Hackett G et al. Treating men with predominantly nonpsychogenic erectile dysfunction with intracavernosal vasoactive intestinal polypeptide and phentolamine mesylate in a novel auto-injector system: a multicentre double-blind placebo-controlled study. BJU Int 1999 83 : 274 9
24. Hackett G, Larsen F. Clinical experience with Invicorp at Good Hope Hospital ED Clinic, 1996-2006. J Sex Med 2007 4 : 134
25. Sandhu D, Curless E, Dean J et al. A double blind, placebo controlled study of intracavernosal vasoactive intestinal polypeptide and phenotolamine mesylate in a novel auto-injector for the treatment of non-psychogenic erectile dysfunction. Int J Impot Res 1999 11 : 91 7
26. McMahon CG. A pilot study of the role of intracavernous injection of vasoactive intestinal peptide (VIP) and phentolamine mesylate in the treatment of erectile dysfunction. Int J Impot Res 1996 8 : 233 6
27. Kim N. Potentiation of VIP-induced relaxation by phentolamine in corpus cavernosum. Int J Imp Res 1998 10 : A327
28. Committee for Proprietary Medicinal Products. Note for guidance on Fixed Combination Medicinal Products. Cited; CPMP/CWP240/95:1996 Available at: http://www.emea.europa.eu/pdfs/human/ewp/024095en.pdf. Accessed March 2008
29. Keijzers GB. Aviptadil (Senatek). Curr Opin Invest Drugs 2001 2 : 545 9
30. Porst H. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol 1996 155 : 802 15
31. Gerstenberg T. Long term use of vasopotin in the treatment of erectile dysfunction. Int J Imp Res 1995 7 : S5
32. Shah PJ, Dinsmore W, Oakes RA, Hackett G. Injection therapy for the treatment of erectile dysfunction: a comparison between alprostadil and a combination of vasoactive intestinal polypeptide and phentolamine mesilate. Curr Med Res Opin 2007 23 : 2577 83
33. Junemann KP, Manning M, Krautschick A, Alken P. 15 years of injection therapy in erectile dysfunction: a review. Int J Imp Res 1996 8 : A60
34. Porst H, Buvat J, Meuleman E, Michal V, Wagner G. Final results of a prospective multicenter-study with self-injection therapy with PGE1 after 4 years of follow-up. Int J Imp Res 1996 8 : D118
35. Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group N Engl J Med 1996 334 : 873 7